Lipids, Inflammation and Insulin Action

脂质、炎症和胰岛素作用

基本信息

  • 批准号:
    6827062
  • 负责人:
  • 金额:
    $ 45.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-06-01 至 2008-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal deals with biology of adipocyte/macrophage fatty acid binding proteins (FABPs) as a model experimental system as they relate to the molecular mechanisms of obesity. FABPs are a family of cytoplasmic proteins expressed in a variety of cell types and bind to fatty acids, xenobiotics and retinoic acid. White adipocytes and macrophages co-express two FABP isoforms, aP2 and mal1, which have critical functions in both metabolic and inflammatory responses. Mice lacking aP2 have reduced insulin resistance associated with obesity, improved lipid metabolism and dramatically protected from atherosclerosis. The latter is predominantly related to the action of aP2 in macrophages. Mal1-deficient animals also exhibit moderately increased insulin sensitivity and altered lipid metabolism. Recently, we developed a mouse model lacking both aP2 and mall (aP2-mal1-/-) to determine the impact of these FABPs on systemic metabolic control. Interestingly, and unlike the individual FABP mutants, the aP2- mal1-/- mice are resistant to weight gain and increased adiposity and maintained their lean body mass on a high fat diet with no reduction in food intake but a significant increase in muscle AMP-activated kinase (AMP-K) activity. In the ob/ob model, the reduced adiposity phenotype and the increase in AMP-K activity are lost. However, in preliminary studies, aP2-mal1-deficient mice were dramatically protected against insulin resistance and fatty liver disease associated with either dietary or genetic obesity. We propose to study the impact of aP2-mal1-combined deficiency in detail with respect to adipogenesis and obesity using dietary and genetic (leptin-deficient) models. We will address the target cell types involved in this action of FABPs and address the potential involvement of macrophages. We will also address the role of AMP-kinase activation in muscle as a mechanism of increased fatty acid utilization, energy expenditure and weight reduction and test the sensitivity of peripheral organs to adipocyte-derived hormones leptin and adiponectin in the presence and absence of FABPs. We will develop additional experimental systems to generate insights into the mechanisms of action of aP2 and mal1, identify protein interactions with these FABPs in their target cells and study the pathways underlying their biology with respect to obesity. The adipocyte/macrophage fatty acid binding proteins play a central role in obesity and the associated disorders in mice and provide an outstanding tool to study the underlying mechanisms to many key components of the metabolic syndrome. The proposed studies will provide important insights regarding the mechanisms by which FABPs integrate inflammatory and metabolic pathways regulate systemic energy homeostasis.
描述(由申请人提供):本提案涉及脂肪细胞/巨噬细胞脂肪酸结合蛋白(FABPs)的生物学作为一个模型实验系统,因为它们与肥胖的分子机制有关。FABPs是一个细胞质蛋白家族,在多种细胞类型中表达,并与脂肪酸、异种生物制剂和视黄酸结合。白色脂肪细胞和巨噬细胞共同表达两种FABP亚型aP2和mal1,这两种亚型在代谢和炎症反应中都具有关键功能。缺乏aP2的小鼠减少了与肥胖相关的胰岛素抵抗,改善了脂质代谢,并显著地保护了动脉粥样硬化。后者主要与aP2在巨噬细胞中的作用有关。mal1缺陷动物也表现出胰岛素敏感性适度升高和脂质代谢改变。最近,我们建立了一个缺乏aP2和mall (aP2-mal1-/-)的小鼠模型,以确定这些FABPs对全身代谢控制的影响。有趣的是,与单个FABP突变体不同,aP2- mal1-/-小鼠对体重增加和脂肪增加有抵抗力,并在高脂肪饮食中保持瘦体重,食物摄入量没有减少,但肌肉amp活化激酶(AMP-K)活性显著增加。在ob/ob模型中,减少的肥胖表型和AMP-K活性的增加消失了。然而,在初步研究中,ap2 -mal1缺陷小鼠可显著防止胰岛素抵抗和与饮食或遗传性肥胖相关的脂肪肝疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GOKHAN S HOTAMISLIGIL其他文献

GOKHAN S HOTAMISLIGIL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GOKHAN S HOTAMISLIGIL', 18)}}的其他基金

Role of Adipokine FABP4 in Glucoregulation and Counter Regulatory Responses
脂肪因子 FABP4 在血糖调节和反调节反应中的作用
  • 批准号:
    10530591
  • 财政年份:
    2019
  • 资助金额:
    $ 45.83万
  • 项目类别:
Novel pathways controlling macrophage inflammation and resolution in atherosclerosis
控制巨噬细胞炎症和动脉粥样硬化消退的新途径
  • 批准号:
    10216329
  • 财政年份:
    2019
  • 资助金额:
    $ 45.83万
  • 项目类别:
Role of Adipokine FABP4 in Glucoregulation and Counter Regulatory Responses
脂肪因子 FABP4 在血糖调节和反调节反应中的作用
  • 批准号:
    10304199
  • 财政年份:
    2019
  • 资助金额:
    $ 45.83万
  • 项目类别:
Novel pathways controlling macrophage inflammation and resolution in atherosclerosis
控制巨噬细胞炎症和动脉粥样硬化消退的新途径
  • 批准号:
    10450684
  • 财政年份:
    2019
  • 资助金额:
    $ 45.83万
  • 项目类别:
The role of immunometabolic pathways in atherosclerosis
免疫代谢途径在动脉粥样硬化中的作用
  • 批准号:
    8967582
  • 财政年份:
    2014
  • 资助金额:
    $ 45.83万
  • 项目类别:
The role of immunometabolic pathways in atherosclerosis
免疫代谢途径在动脉粥样硬化中的作用
  • 批准号:
    9171375
  • 财政年份:
    2014
  • 资助金额:
    $ 45.83万
  • 项目类别:
Deconvolution of adaptive metabolic responses of the endoplasmic reticulum
内质网适应性代谢反应的反卷积
  • 批准号:
    8047403
  • 财政年份:
    2010
  • 资助金额:
    $ 45.83万
  • 项目类别:
Lipids, Inflammation and Insulin Action
脂质、炎症和胰岛素作用
  • 批准号:
    7996838
  • 财政年份:
    2009
  • 资助金额:
    $ 45.83万
  • 项目类别:
Lipids, Inflammation and Insulin Action
脂质、炎症和胰岛素作用
  • 批准号:
    8409824
  • 财政年份:
    2004
  • 资助金额:
    $ 45.83万
  • 项目类别:
Lipids, Inflammation and Insulin Action
脂质、炎症和胰岛素作用
  • 批准号:
    7583753
  • 财政年份:
    2004
  • 资助金额:
    $ 45.83万
  • 项目类别:

相似海外基金

Adenylate Kinase 2 Deficiency and the Failure of Myelopoiesis
腺苷酸激酶 2 缺乏和骨髓生成失败
  • 批准号:
    10906528
  • 财政年份:
    2023
  • 资助金额:
    $ 45.83万
  • 项目类别:
Adenylate Kinase 2 Deficiency and the Failure of Myelopoiesis
腺苷酸激酶 2 缺乏和骨髓生成失败
  • 批准号:
    10446518
  • 财政年份:
    2022
  • 资助金额:
    $ 45.83万
  • 项目类别:
Adenylate Kinase 2 Deficiency and the Failure of Myelopoiesis
腺苷酸激酶 2 缺乏和骨髓生成失败
  • 批准号:
    10583534
  • 财政年份:
    2022
  • 资助金额:
    $ 45.83万
  • 项目类别:
Probing adenylate kinase-dependent CFTR gating in vivo and as therapeutic target
体内探索腺苷酸激酶依赖性 CFTR 门控并作为治疗靶点
  • 批准号:
    9383695
  • 财政年份:
    2017
  • 资助金额:
    $ 45.83万
  • 项目类别:
Probing adenylate kinase-dependent CFTR gating in vivo and as therapeutic target
体内探索腺苷酸激酶依赖性 CFTR 门控并作为治疗靶点
  • 批准号:
    10004609
  • 财政年份:
    2017
  • 资助金额:
    $ 45.83万
  • 项目类别:
Probing adenylate kinase-dependent CFTR gating in vivo and as therapeutic target
体内探索腺苷酸激酶依赖性 CFTR 门控并作为治疗靶点
  • 批准号:
    9135633
  • 财政年份:
    2015
  • 资助金额:
    $ 45.83万
  • 项目类别:
Redox regulation of human adenylate kinase 2 (AK2), an essential key controller of energy metabolism
人腺苷酸激酶 2 (AK2) 的氧化还原调节,能量代谢的关键控制器
  • 批准号:
    251546152
  • 财政年份:
    2014
  • 资助金额:
    $ 45.83万
  • 项目类别:
    Priority Programmes
Mechanisms and Binding-Sites in Adenylate Kinase-Dependent CFTR Gating
腺苷酸激酶依赖性 CFTR 门控的机制和结合位点
  • 批准号:
    8115794
  • 财政年份:
    2009
  • 资助金额:
    $ 45.83万
  • 项目类别:
Mechanisms and Binding-Sites in Adenylate Kinase-Dependent CFTR Gating
腺苷酸激酶依赖性 CFTR 门控的机制和结合位点
  • 批准号:
    8517797
  • 财政年份:
    2009
  • 资助金额:
    $ 45.83万
  • 项目类别:
Mechanisms and Binding-Sites in Adenylate Kinase-Dependent CFTR Gating
腺苷酸激酶依赖性 CFTR 门控的机制和结合位点
  • 批准号:
    7915409
  • 财政年份:
    2009
  • 资助金额:
    $ 45.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了